Patents by Inventor Richard W. Ransom

Richard W. Ransom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cloned and expressed human bradykinin BK-2 receptor
    Patent number: 6407207
    Abstract: The present invention is a cloned human BK-2 bradykinin receptor cloned from a human lung fibroblast cell line. A cDNA clone, also part of the instant invention, encodes a novel 364 amino acid protein (the BK-2 receptor) that has the characteristics of a seven transmembrane domain G-protein coupled receptor. The invention is used to express a BK-2 bradykinin receptor in a host mammalian cell to screen for pharmaceutical antagonists or agonists which bind to or interact with the BK-2 bradykinin receptor protein.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: June 18, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Joseph A. Borkowski, John W. Hess, Catherine D. Strader, Richard W. Ransom
  • Muscarine antagonists
    Patent number: 5756508
    Abstract: This invention is concerned with novel 1,3-dihydro-1-?1-(1-heteroarylpiperidin-4-yl)piperidin-4-yl!-2H-benzimidaz olones, derivatives thereof, their preparation, method of use and pharmaceutical compositions. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thompson, Richard W. Ransom, Pierre Mallorga, Michael F. Sugrue
  • Muscarine agonists
    Patent number: 5718912
    Abstract: This invention is concerned with novel 1-?cycloalkylpioeridin-4-yl!-2H benzimidazolones, their compositions and method of use. The novel compounds are selective muscarinic agonists of the m2 subtype with low activity at the m3 subtype. The compounds are effective for the treatment of glaucoma with fewer side effects than the pilocarpine therapy.
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thomspon, Pierre Mallorga, Richard W. Ransom, Ian M. Bell, Michael F. Sugrue, Peter M. Munson
  • Muscarine antagonists
    Patent number: 5691323
    Abstract: Compounds, 1,3-dihydro-1-{1-?piperidin-4-yl!piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazol-2-ones and derivatives thereof, their preparation, method of use and pharmaceutical compositions are described. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thompson, Michael F. Sugrue, Richard W. Ransom, Pierre J. Mallorga, Ian M. Bell, Anthony M. Smith
  • Muscarine antagonists
    Patent number: 5574044
    Abstract: Compounds, 1,3-dihydro-1-{1-[piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazol-2-ones and derivatives thereof, their preparation, method of use and pharmaceutical compositions are described. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: November 12, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thompson, Michael F. Sugrue, Richard W. Ransom, Pierre J. Mallorga, Ian M. Bell, Anthony M. Smith
  • Pyrroloquinoline Bradykinin antagonist
    Patent number: 5288725
    Abstract: A pyrroloquinoline compound of the following formula is disclosed: ##STR1## wherein H,C.sub.1-6 alkyl,R.sup.1 is: ##STR2## wherein R is H, C.sub.1-10 alkyl, or C.sub.1-6 alkyloxycarbonyl; R.sup.2 is:H,C.sub.1-6 alkyl, ##STR3## wherein R.sup.5 is C.sub.1-10 alkyl, aryl, or aryl C.sub.1-10 alkyl; R.sup.3 is:(CH.sub.2).sub.n NHR wherein R is H, C.sub.1-6 alkyl, or C.sub.1-6 alkyloxycarbonyl; ##STR4## R.sup.4 is: H,C.sub.1-6 alkyl,C.sub.1-6 alkyloxycarbonyl,RCH.sub.2 --, wherein R is H, C.sub.1-6 alkyl or aryl, or ##STR5## X is O, or NR.sup.6 wherein R.sup.6 is equal to H or C.sub.1-6 alkyl and n is an integer from 1-3.The compounds of the invention exhibit bradykinin antagonist activity as well as activity with .alpha.-adrenergic, histaminergic, and muscarinic receptors.
    Type: Grant
    Filed: October 15, 1992
    Date of Patent: February 22, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Keith M. Witherup, Richard W. Ransom, Sandor L. Varga, Steven M. Pitzenberger, Victor J. Lotti, William J. Lumma
  • Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
    Patent number: 5250558
    Abstract: Substituted triazolinone, triazolinethione, and triazolinimine compounds of formula (I) are as neurotensin II antagonists.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: October 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, Richard W. Ransom
  • Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
    Patent number: 5204354
    Abstract: Substituted quinazolinones of the formula are useful as neurotensin antagonists.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: April 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Prasun K. Chakravarty, E. M. Naylor, Richard W. Ransom